Phase 1, Open-Label, Randomized, Single-Dose, 4-Treatment, 4-Period Crossover Bioequivalence Study Comparing 25 Mg and 50 Mg Formulations of DVS-233 SR and Investigate Food Effect on 50 Mg Formulations of DVS-233 SR Tablet Under Fed and Fasted Conditions.
Latest Information Update: 30 Jan 2012
At a glance
- Drugs Desvenlafaxine (Primary)
- Indications Major depressive disorder
- Focus Pharmacokinetics
Most Recent Events
- 26 Jan 2012 Actual patient number (41) added as reported by ClinicalTrials.gov.
- 12 Nov 2010 Actual end date (Nov 2010) added as reported by ClinicalTrials.gov.
- 12 Nov 2010 Actual initiation date (Sep 2010) added as reported by ClinicalTrials.gov.